Abeona Therapeutics (ABEO) Income from Continuing Operations (2011 - 2026)
Abeona Therapeutics (ABEO) recorded quarterly Income from Continuing Operations of 17075000.0 in Q1 2026, up 16.54% quarter-over-quarter from 20460000.0 in Q4 2025, and down 41.95% on a YoY basis from 29413600.89 in Q1 2025.
Abeona Therapeutics (ABEO) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Abeona Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 17075000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 41.95% year-over-year to 17075000.0; the TTM figure through Mar 2026 stood at 81649000.0 (up 284.79% YoY), while the FY2025 annual figure was 71183000.0, up 211.69% from the prior year.
- Income from Continuing Operations was 17075000.0 for Q1 2026 at Abeona Therapeutics, up from 20460000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 124345000.0 in Q2 2025 to a low of 30269000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 4528882.35 across 5 years, with a median of 12029000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 164.61% in 2024, then jumped 1578.98% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 13114000.0 in 2022, then declined by 1.56% to 13318000.0 in 2023, then jumped by 30.22% to 9293000.0 in 2024, then slumped by 120.17% to 20460000.0 in 2025, then grew by 16.54% to 17075000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 17075000.0 (Q1 2026), 20460000.0 (Q4 2025), and 5161000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Abeona Therapeutics | 309.15 Mn | 140.88 Mn | 6.02 Mn | -17.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.08 Mn |
| Dec 31, 2025 | -20.46 Mn |
| Sep 30, 2025 | -5.16 Mn |
| Jun 30, 2025 | 124.35 Mn |
| Mar 31, 2025 | -12.03 Mn |
| Dec 31, 2024 | -9.29 Mn |
| Sep 30, 2024 | -30.27 Mn |
| Jun 30, 2024 | 7.41 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.32 Mn |
| Sep 30, 2023 | -11.44 Mn |
| Jun 30, 2023 | -10.66 Mn |
| Mar 31, 2023 | -12.14 Mn |
| Dec 31, 2022 | -13.11 Mn |
| Sep 30, 2022 | -9.54 Mn |
| Jun 30, 2022 | -8.18 Mn |
| Mar 31, 2022 | -20.79 Mn |
| Dec 31, 2021 | -46.67 Mn |
| Sep 30, 2021 | -15.55 Mn |
| Jun 30, 2021 | -15.21 Mn |